进行性遗传性肝内胆汁淤积 2 型治疗市场：依药物、配销通路、地区划分

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, By Distribution Channel, and By Region

出版日期: 2023年09月26日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球进行性遗传性肝内胆汁淤积2型治疗市场估计为7,860万美元，预计在预测期内（2023-2030年）年复合成长率为40.56%。

报告范围		报告详情
基准年	2022年	2023年市场规模	7860 万美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	39.80%	2030年市场规模预测	8.188 亿美元

图 1. 2023 年治疗 2 型进行性遗传性肝内胆汁淤积症的全球市场占有率（按药物划分）

进行性遗传性肝内胆汁淤积是指由胆汁分泌机制缺陷引起的一系列罕见遗传性疾病。通常分为三种亚型：PFIC 1 型、PFIC 2 型和 PFIC 3 型。此疾病通常在生命早期被诊断出来，并经常出现肝内胆汁淤积的征兆和症状，例如搔痒、尿色深、粪便苍白、食慾不振和疲劳。 ABCB11 基因突变是 PFIC2 的原因。 ABCB11 基因提供製造称为胆盐输出帮浦 (BSEP) 的蛋白质的指令。这种蛋白质存在于肝臟中，主要作用是将胆盐（胆汁的成分）转运出肝细胞。 ABCB11 基因突变会导致胆盐在肝细胞中积聚，损害肝细胞并导致肝病。

市场动态

製药业的主要参与者专注于开发新药和寻找新的作用机制来治疗进行性遗传性2 型肝内胆汁淤积症。因此，此类新产品的引进预计将在预测期内推动全球进行性遗传性肝内胆汁淤积2型治疗市场的成长。例如，2023年2月14日，生物製药公司Mirum Pharmaceuticals, Inc.推出了一款治疗2个月或以上进行进行性遗传性肝内胆汁淤积（PFIC）患者胆汁淤积性瘙痒的药物。我们宣布已提交补充申请LIVMARLI（maralixibat）口服溶液的新药认证申请（sNDA）。此 sNDA 备案是根据 LIVMARLI 3 月 PFIC sPhase 3 研究的资料。 MARCH PFIC 研究是有史以来规模最大的 PFIC 随机试验，招募了 93 名患者，涉及多种遗传 PFIC 亚型，包括 PFIC1、PFIC2、PFIC3、PFIC4、PFIC6 和突变状态未知。

本次测试的主要特点

本报告详细分析了全球进行性遗传性肝内胆汁淤积2型治疗市场，并介绍了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率。
它还阐明了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
本报告根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球进行性遗传性肝内胆汁淤积 2 型治疗市场的主要参与者。
该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
全球进行性遗传性肝内胆汁淤积 2 型治疗市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。我是。
相关人员可以透过用于分析全球进行性遗传性肝内胆汁淤积 2 型治疗市场的各种策略矩阵来促进决策。

公司简介
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi SA
- Mylan NV
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Jadeite Medicines Inc.
- Ipsen Pharma
- Analyst's Views

第9章章节

参考
调查方法

简介目录

Product Code: CMI4399

The global progressive familial intrahepatic cholestasis type 2 treatment market is estimated to be valued at US$ 78.6 Million in 2023 and is expected to exhibit a CAGR of 40.56% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 78.6 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	39.80%	2030 Value Projection:	US$ 818.8 Mn

Figure 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share (%), By Drug, 2023

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - IMG1

Progressive familial intrahepatic cholestasis refers to a collection of rare genetic disorders due to defective mechanisms of bile secretion. Typically divided into three subtypes, PFIC type 1, PFIC type 2, and PFIC type 3. The condition is usually diagnosed in the early years of life and often presents with signs and symptoms of intrahepatic cholestasis, such as pruritis, dark urine, pale stool, loss of appetite, and fatigue. Mutations in the ABCB11 gene are responsible for PFIC2. The ABCB11 gene provides instructions for making a protein called the bile salt export pump (BSEP). The protein is found in the liver, and its main role is to move bile salts (a component of bile) out of liver cells. Mutations in the ABCB11 gene result in the buildup of bile salts in liver cells, damaging these cells and causing liver disease.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs and accessing new mechanisms of action to treat progressive familial intrahepatic cholestasis type 2. Thus, the introduction of such new products into the market is expected to drive growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. For instance, on February 14, 2023, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the company has submitted a supplemental New Drug Application (sNDA) for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC). The sNDA submission is based on data from the March PFIC sPhase 3 study of LIVMARLI. MARCH PFIC is the largest randomized trial conducted in PFIC, with 93 patients across a range of genetic PFIC subtypes, including PFIC1, PFIC2, PFIC3, PFIC4, PFIC6 and unidentified mutational status.

Key features of the study:

This report provides an in-depth analysis of the global progressive familial intrahepatic cholestasis type 2 treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatments market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Jadeite Medicines Inc., and Ipsen Pharma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive familial intrahepatic cholestasis type 2 treatment market

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Detailed Segmentation:

By Drug:
- Ursodeoxycholic acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi S.A.
- Mylan N.V.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Jadeite Medicines Inc.
- Ipsen Pharma

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Recent Trends & Key Developments
Regulatory Scenario
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Ursodeoxycholic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
U.S.
Canada
Europe
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Market Size and Forecast, Y-o-Y Growth By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Mn)
North Africa
Central Africa
South Africa